Quantcast

Latest AstraZeneca Stories

2014-05-15 08:32:20

Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that it has received a $25 million milestone payment from AstraZeneca (NYSE:AZN, LON:AZN) for the initiation of a Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia, or elevated...

2014-05-14 08:30:37

BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, binimetinib (MEK162) (co-developing with Novartis) and selumetinib (licensed to AstraZeneca) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 30 - June 3, 2014 in Chicago, Illinois. Both MEK inhibitors are advancing in Phase 3 or pivotal trials: binimetinib is being evaluated in NRAS- and BRAF-mutant...

2014-05-13 23:15:13

The Department of Economic Development for the City of Frederick is proud to announce that AstraZeneca, and its global biologics research and development arm MedImmune, received an “Economic Development Project” award at the Maryland Economic Development Association (MEDA) 2014 Annual Conference on Monday, April 28, 2014. The award recognized the 385,000 square foot, $600 million manufacturing facility that opened in August 2011. Frederick, Maryland (PRWEB) May 13, 2014 Richard...

2014-05-12 08:30:24

BEIJING, May 12, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2014, after market closes on Wednesday, May 21, 2014 EDT. The Company will host a conference call prior to the market opening on Thursday, May 22, 2014, at 8:00 a.m. EDT (Thursday, May 22, 2014 at 8:00 p.m. China Standard Time) to review the...

2014-05-09 16:24:31

Study Evaluating Novel Investigational IL-17 Receptor Antibody Meets All Primary and Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1(TM) study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the...

2014-05-06 04:23:22

WILMINGTON, Del., May 6, 2014 /PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced the US Food and Drug Administration (FDA) approved EPANOVA(®) (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL). To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/7192251-astrazeneca-fda-approval EPANOVA is the first FDA approved...

2014-05-02 16:24:31

ReportsnReports.com adds "Market Research Report on Global and Chinese Propofol Industry, 2009-2019" to its store. DALLAS, May 2, 2014 /PRNewswire-iReach/ -- This is a professional and in-depth market survey on Global and Chinese Propofol industry. The report firstly reviews the basic information of Propofol including its classification, application and manufacturing technology. The report then explores global and China's top manufacturers of Propofol listing their product...

2014-05-02 08:25:27

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 2, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Boston Scientific Corporation (NYSE: BSX), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Illumina Inc. (NASDAQ: ILMN) and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited...

2014-04-30 23:12:14

MarketReportsOnline.com adds "Global Influenza (Flu) Vaccine Market: Trends & Opportunities (2014-19)" report to its research store. Dallas, Texas (PRWEB) April 30, 2014 The report titled “Global Influenza (Flu) Vaccine Market: Trends and Opportunities (2014-2019)” provides an insight into the market dynamics and various trends and opportunities associated with the global Influenza vaccine market. It covers the global market size and growth dynamics of the influenza...

2014-04-30 23:09:43

Awards Announced from Bio-IT World Conference & Expo in Boston Boston, Mass (PRWEB) April 30, 2014 Bio-IT World announced the winners of its tenth annual Best Practices Awards competition this morning in a plenary session at the 2014 Bio-IT World Conference & Expo in Boston. Grand prize winners were named in five life sciences categories highlighting best practices in clinical trial IT, research infrastructure, bioinformatics, cloud computing and data management from AstraZeneca...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related